Searched for
MONOPOLY IN DRUG MARKET
Pharma body renews push for data protectionLeading pharmaceutical companies seek Regulatory Data Protection to boost research investments. Public health groups and local makers oppos...- Cancer drug prices raised 50% as NPPA acts on shortage concernsIndia's drug pricing authority has approved a 50% price hike for essential anti-cancer drugs carboplatin and cisplatin. This decision follo...
- US raises concerns at India’s duties on IP-intensive goods, source code, AI working paperThe US has voiced concerns over India's high customs duties on IP-intensive products and its proposed mandatory blanket license for AI deve...
- Budget 2025: 'Customs waiver on life-saving drugs won't benefit most patients'Despite the import duty waiver on life-saving drugs for rare diseases announced in the union budget, patients might not benefit due to high...
- View: How to get vaccines speedily to people who need them, once one has been foundThe constant flow of important breakthroughs in modern medicine has produced radical advances in the treatment of a wide range of diseases....
- Activists cry foul over new HIV drug monopolyOnly one Indian drug maker, Emcure, will be allowed to sell the medicine in the Indian private market, because of a licensing agreement wit...
- Drug firms facing challenging times due to price control: CiplaCipla is keeping all avenues open for appropriate licensing agreements with other global companies to make patients better secured for affo...
- Japan seeks patent term extension at Regional Comprehensive Economic PartnershipRCEP is a proposed free trade agreement among the 10-member Association of Southeast Asian Nations and Australia, China, India, Japan, Sout...
- PMEAC comes up with 3 pricing models to fix retail prices of 328 drugsPMEAC has suggested a complex combination of three pricing models to fix retail prices of 348 essential drugs to balance industry's concern...
- 2011: An uncomfortable year for pharmaceutical sectorThe pharmaceutical industry will remember 2011 as a year in which the government sought more to exercise more control over the business.
- Centre to talk MNC pharma cos into keeping a check on pricesA government move to regulate prices of patented medicines imported and marketed in India by multinational drug-makers may come as a big re...
- New norms for MNC drug pricesGovt may soon finalise norms for monitoring prices of costly imported patented medicines for diseases such as diabetes, arthritis, obesity,...
- Pharma dept wants drug controller's office under its ambitThe newly-formed department of pharmaceuticals wants to take Drug Controller General of India (DCGI) under its control.
- Price-controlled drug’s new formula needs NPPA nodDrug makers will find it increasingly difficult to dodge government control over prices by altering the composition of their brands.
- NPPA calls for price check on 'worm' drugThe country’s drug price regulator has recommended price control of a mass-use medicine for worm-infestation sold by more than 80 companies.
- Local cos can eye patents in USUS Congress is set to give a new inexpensive option for Indian drug makers to attack the patents.
- Reddy panel holds hope for drug cosWhile MNC drug makers have reasons to smile at Satwant Reddy panel’s view that their new formulations be protected from ‘unfair competition...
- US senators move bill to ban copycat generics productsThree US senators have introduced a bill in the US senate to try and prevent global pharma giants from selling cheaper copies of their own ...
- MNCs to pay for data exclusivityFor multinational pharma giants, slowing down the entry of cheaper copies of their new drugs in India may come at a price.
- How will amendments to Patents Bill help pharma?The amendments address the demands for making the law more friendly to the domestic pharmaceutical industry, while meeting international ob...
Load More
